Advertisement
Advanced Search

References

  1. [1]Desai, J., Yassa, L., Marqusee, E. et al, Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med. 2006;145:660–664.
  2. [2]Rini, B.I., Tamaskar, I., Shaheen, P. et al, Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst. 2007;99:81–83.
  3. [3]Porta, C., Paglino, C., Imarisio, I. et al, Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib. Clin Exp Med. 2007;7:127–134.
  4. [4]Feldman, D.R., Martorella, A.J., Robbins, R.J. et al, Re: hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst. 2007;99:974–975.
  5. [5]Faris, J.E., Moore, A.F., Daniels, G.H. Sunitinib (sutent)-induced thyrotoxicosis due to destructive thyroiditis: a case report. Thyroid. 2007;17:1147–1149.

Related Articles

Searching for related articles..

Advertisement